Skip to main content
Lupin Ltd logo

Lupin Ltd — Investor Relations & Filings

Ticker · LUPIN ISIN · INE326A01037 LEI · 335800HHXTESDEE2FC65 BSE.NS Manufacturing
Open in API
Filings indexed 3,180 across all filing types
Latest filing 2023-06-29 Regulatory Filings
Country IN India
Listing BSE.NS LUPIN

About Lupin Ltd

https://www.lupin.com/

Lupin Ltd is a global pharmaceutical organization specializing in the development, manufacturing, and marketing of a comprehensive range of generic and branded formulations, biotechnology products, and active pharmaceutical ingredients. The company holds a significant market position in therapeutic segments such as cardiovascular, diabetology, asthma, pediatrics, gastrointestinal, anti-infectives, and non-steroidal anti-inflammatory drugs. It is notably recognized for its leadership in the anti-tuberculosis medication sector. With a strong emphasis on research and development, Lupin focuses on complex generics, specialty medicines, and biosimilars. The company operates advanced manufacturing facilities and maintains a substantial commercial presence across major global markets, including North America, Europe, and the Asia-Pacific region, delivering affordable and high-quality healthcare solutions.

Recent filings

Filing Released Lang Actions
Loss of Share Certificates
Regulatory Filings Classification · 95% confidence The document text is extremely short (1067 characters) and contains only digital signature information without any substantive content related to financial performance, management changes, voting results, or other report types. There is no mention of any report, announcement, or financial data. Given the lack of content and the presence of digital signatures only, this document does not fit into any specific report category and is best classified as a Regulatory Filing (RNS), which serves as a fallback category for miscellaneous filings that do not fit elsewhere.
2023-06-29 English
Intimation regarding loss of share certificate by the shareholder.
Regulatory Filings Classification · 95% confidence The document text is extremely short (1014 characters) and contains only digital signature information without any substantive content related to financial reports, announcements, or filings. There is no mention of any report type, financial data, regulatory body, or corporate event. Given the lack of content and the nature of the text, it does not fit into any specific filing category and defaults to the fallback category for miscellaneous filings.
2023-06-29 English
Lupin Launches Rufinamide Oral Suspension in the United States.
Regulatory Filings Classification · 95% confidence The document is a press release announcing the launch of a pharmaceutical product (Rufinamide Oral Suspension) by Lupin Limited. It is addressed to stock exchanges as a disclosure pursuant to Regulation 30 of SEBI Listing Regulations, which typically covers material events or information about the company. The document is short (3691 characters), contains no financial statements or detailed financial analysis, and is primarily an announcement of a business event rather than a financial report or regulatory filing. It does not fit categories like Annual Report, Interim Report, Earnings Release, or Management Reports. It is not a report publication announcement since it is the actual announcement content. The best fitting category is Capital/Financing Update (CAP) as it relates to a significant business development that could impact the company's market position and investor information, or alternatively Regulatory Filings (RNS) as a general disclosure. However, since it is a product launch announcement disclosed under Regulation 30, which is often classified under Regulatory Filings, the most appropriate classification is Regulatory Filings (RNS).
2023-06-23 English
Press Release
Regulatory Filings Classification · 95% confidence The document is a press release announcing the launch of a pharmaceutical product (Rufinamide Oral Suspension) by Lupin Limited. It is addressed to stock exchanges and references a disclosure pursuant to Regulation 30 of SEBI Listing Regulations, which typically relates to material events or corporate announcements. The document does not contain financial statements, detailed financial analysis, or management discussion. It is a corporate announcement about a product launch, not a financial report or regulatory filing of financial results. The length is 3685 characters, which is relatively short and consistent with a press release or announcement. Therefore, the document fits best under the category of Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory announcements that do not fit other specific categories.
2023-06-23 English
Disclosure in respect of allotment of 17466 shares under ESOP.
Regulatory Filings Classification · 100% confidence The document text is extremely short (566 characters) and contains only a digital signature block with no substantive content related to financial reports, announcements, or filings. There is no mention of any report type, financial data, regulatory body, or corporate event. Given the lack of content and the nature of the text, it does not fit any specific filing category and defaults to the fallback category for miscellaneous filings.
2023-06-22 English
ESOP/ESOS/ESPS
Regulatory Filings Classification · 95% confidence The document text is extremely short (561 characters) and contains only a digital signature block with no substantive content related to financial performance, management changes, or any report details. There is no mention of any report, meeting, or financial data. This appears to be a certification or attestation by an individual rather than a full report or announcement. According to the CERTIFICATION RULE, such documents should be classified as Regulatory Filings (RNS).
2023-06-22 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.